Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

2.00
-0.0050-0.25%
Volume:315.90K
Turnover:628.25K
Market Cap:87.29M
PE:-3.93
High:2.03
Open:2.01
Low:1.93
Close:2.01
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:0.97
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:7.73
PE(LYR):-3.27

Loading ...

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Prothena (PRTA)

TIPRANKS
·
Aug 15

Gain Therapeutics (GANX) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 13

Inovio Q2 Net Loss Narrows on Warrant Gain, Lower Costs

Reuters
·
Aug 13

BTIG Sticks to Their Buy Rating for Gain Therapeutics (GANX)

TIPRANKS
·
Aug 12

Acumen Pharmaceuticals Q2 Net Loss Widens, Misses Analyst Estimates

Reuters
·
Aug 12

Gain Therapeutics Price Target Maintained with a $5.00/Share by BTIG

Dow Jones
·
Aug 12

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

Gain Therapeutics Climbs on Narrower-than-Expected Quarterly Loss

Reuters
·
Aug 11

Gain Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs

Reuters
·
Aug 11

Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate

Benzinga Earnings
·
Aug 11

Gain Therapeutics Q2 Net Loss Per Share Narrows as R&D Expenses Fall

Reuters
·
Aug 11

Gain Therapeutics reports Q2 EPS (11c), consensus (15c)

TIPRANKS
·
Aug 11

Gain Therapeutics Q2 EPS USD -0.11

THOMSON REUTERS
·
Aug 11

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 11

Gain Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Gain Therapeutics Extends Cash Runway Into 2027 Operations

TIPRANKS
·
Jul 17

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Promotes Terenzio Ignoni to COO

Reuters
·
Jul 16

Gain Therapeutics - to Commence Phase 2 Study of Rexaceract in Q3 2026

THOMSON REUTERS
·
Jul 16

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

THOMSON REUTERS
·
Jul 16